Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using Kinect

Muscle and Nerve

Volumn 52, Issue 3, 2015, Pages 344-355

  Han, Jay J ^a   Kurillo, Gregorij ^a,b   Abresch, Richard T ^a   De Bie, Evan ^a   Nicorici, Alina ^a   Bajcsy, Ruzena ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Becker; Duchenne; Kinect; Reachable workspace; Upper extremity

Indexed keywords

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARM DISEASE; ARTICLE; BECKER MUSCULAR DYSTROPHY; BROOKE SCALE; CHILD; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HUMAN; KINECT SENSOR; MAJOR CLINICAL STUDY; MALE; NEUROQOL QUESTIONNAIRE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SELF REPORT; SENSITIVITY ANALYSIS; SENSOR; UPPER EXTREMITY THREE DIMENSIONAL REACHABLE WORKSPACE; VALIDITY; ARM; CASE CONTROL STUDY; COMPUTER; JOINT CHARACTERISTICS AND FUNCTIONS; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; THREE DIMENSIONAL IMAGING; VIDEO GAME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; COMPUTER PERIPHERALS; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; MUSCULAR DYSTROPHY, DUCHENNE; OUTCOME ASSESSMENT (HEALTH CARE); RANGE OF MOTION, ARTICULAR; UPPER EXTREMITY; VIDEO GAMES; YOUNG ADULT;

EID: 84938968244     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24567     Document Type: Article

References (60)

1. Emery AE. Duchenne muscular dystrophy-Meryon's disease. Neuromuscul Disord 1993;3:263-266.
2. Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years-four states, 2007. MMWR Morb Mortal Wkly Rep 2009;58:1119-1122.
3. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304-313.
4. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
5. Aartsma-Rus A, van Deutekom JC, Fokkema IF, van Ommen GJ, den Dunnen JT. Entries in the Leiden Duchenne Muscular Dystrophy Mutation Database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006;34:135-144.
6. Kunkel LM, Hejtmancik JF, Caskey CT, Speer A, Monaco AP, Middlesworth W, et al. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 1986;322:73-77.
7. Chamberlain JS, Chamberlain JR, Fenwick RG, Ward PA, Caskey CT, Dimnik LS, et al. Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. A multicenter study. JAMA 1992;267:2609-2615.
8. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2:731-740.
9. Hoffman EP. Genotype/phenotype correlations in Duchenne/Becker dystrophy. Mol Cell Biol Hum Dis Serv 1993;3:12-36.
10. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989;39:475-481.
11. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
12. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993;240:98-104.
13. Malik V, Rodino-Klapac LR, Mendell JR. Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs 2012;17:261-277.
14. Clemens PR, Caskey CT. Gene therapy prospects for Duchenne muscular dystrophy. Eur Neurol 1994;34:181-185.
15. Mercuri E, Muntoni F. Muscular dystrophy: new challenges and review of the current clinical trials. Curr Opin Pediatr 2013;25:701-707.
16. Dubowitz V. The Duchenne dystrophy story: from phenotype to gene and potential treatment. J Child Neurol 1989;4:240-250.
17. Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Invest (Lond) 2011;1:1217-1235.
18. Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, van Ommen GJ, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops. Neuromuscul Disord 2008;18:894-903.
19. Stuberg WA, Metcalf WK. Reliability of quantitative muscle testing in healthy children and in children with Duchenne muscular dystrophy using a hand-held dynamometer. Phys Ther 1988;68:977-982.
20. Brooke M, Griggs R, Mendell J, Fenichel G, Shumate J, Pellegrino R. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981;4:186-197.
21. Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010;20:712-716.
22. Smith YA, Hong E, Presson C. Normative and validation studies of the Nine-hole Peg Test with children. Percept Mot Skills 2000;90:823-843.
23. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010;41:500-510.
24. Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil 1969;50:311-319.
25. Bérard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 2005;15:463-470.
26. Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, et al. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 2013;55:1038-1045.
27. Lai JS, Nowinski C, Victorson D, Bode R, Podrabsky T, McKinney N, et al. Quality-of-life measures in children with neurological conditions: Pediatric Neuro-QOL. Neurorehabil Neural Repair 2012;21:697-706.
28. Steffensen B, Hyde S, Lyager S, Mattsson E. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int 2001;6:119-134.
29. Servais L, Deconinck N, Moraux A, Benali M, Canal A, van Parys F, et al. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord 2013;23:139-148.
30. Lowes LP, Alfano LN, Yetter BA, Worthen-Chaudhari L, Hinchman W, Savage J, et al. Proof of concept of the ability of the Kinect to quantify upper extremity function in dystrophinopathy. PLoS Curr 2013;Mar 14:5.
31. Mazzone ES, Vasco G, Palermo C, Bianco F, Galluccio C, Ricotti V, et al. A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Dev Med Child Neurol 2012;54:879-885.
32. NIH Department of Health and Human Services. Action plan for the muscular dystrophies. Plan developed by the Muscular Dystrophy Coordinating Committee Scientific Working Group and approved by the Muscular Dystrophy Coordinating Committee, Bethesda, MD, December 2005.
33. NIH Workshop on Translational Research in Muscular Dystrophy, Silver Spring, MD, June 2007.
34. Muscular Dystrophy Association Clinical Research Coalition Meeting, Tucson, AZ, July 2004.
35. McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013;48:357-368.
36. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013;74:637-647.
37. Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, Fanelli L, et al. 6 minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS One 2014;Jan 8:9(1).
38. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;364:1513-1522.
39. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011;378:595-605.
40. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013;48:343-356.
41. Baiardini I, Minetti C, Bonifacino S, Porcu A, Klersy C, Petralia P, et al. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol 2011;26:707-713.
42. Mendell JR, Csimma C, McDonald CM, Escolar DM, Janis S, Porter JD, et al. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve 2007;35:8-16.
43. U.S. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register. Rockville, MD: FDA Center for Drug Evaluation and Research; 2009. p. 85132-85133.
44. Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration. Value Health 2003;6:522-531.
45. Halder AM, Itoi E, An KN. Anatomy and biomechanics of the shoulder. Orthop Clin N Am 2000;31:159-176.
46. Della Valle CJ, Rokito AS, Birdzell MG, Zuckerman JD. Biomechanics of the shoulder. In: Nordin M, Frankel VH, editors. Basic biomechanics of the musculoskeletal system. Baltimore, MD: Lippincott Williams & Wilkins; 2001.
47. Klopcar N, Lenarcic J. Kinematic model for determination of human arm reachable workspace. Meccanica 2005;40:203-219.
48. Hess SA. Functional stability of the glenohumeral joint. Man Ther 2000;5:63-71.
49. Klopcar N, Tomsic M, Lenarcic J. A kinematic model of the shoulder complex to evaluate the arm-reachable workspace. J Biomech 2007;40:86-91.
50. Davis AM, Beaton DE, Hudak P, Amadio P, Bombardier C, Cole D, et al. Measuring disability of the upper extremity: a rationale supporting the use of a regional outcome measure. J Hand Ther 1999;12:269-274.
51. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. Am J Ind Med 1996;29:602-608. Erratum: Am J Ind Med 1996;30:372.
52. Kurillo G, Han JJ, Abresch RT, Nicorici A, Yan P, Bajcsy R. Development and application of stereo camera-based upper extremity workspace evaluation in patients with neuromuscular diseases. PLoS One 2012;7(9):e45341.
53. Han JJ, Kurillo G, Abresch RT, Nicorici A, Bajcsy R. Validity, reliability, and sensitivity of a 3D vision sensor-based upper extremity reachable workspace evaluation in neuromuscular diseases. PLoS Curr 2013;Dec 12;5.
54. Kurillo G, Chen A, Bajcsy R, Han JJ. Evaluation of upper extremity reachable workspace using Kinect camera. Technol Health Care 2013;21:641-656.
55. Han JJ, Kurillo G, Abresch RT, de Bie E, Nicorici A, Bajcsy R. Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by Kinect. Muscle Nerve 2015;51:168-175.
56. Cella D, Lai JS, Nowinski CJ, Victorson D, Peterman A, Miller D, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 2012;78:1860-1867.
57. Nowinski CJ, Victorson D, Cavazos JE, Gershon R, Cella D. Neuro-QOL and the NIH Toolbox: implications for epilepsy. Therapy 2010;7:533-540.
58. Cella D, Nowinski C, Peterman A, Victorson D, Miller D, Lai JS, et al. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil 2011;92(suppl):S28-36.
59. McDonald CM, Abresch RT, Carter GT, Fowler WM Jr, Johnson ER, Kilmer DD, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995;74(suppl):S70-92.
60. Kurillo G, Han JJ, Nicorici A, Bajcsy R. Tele-MFAsT: Kinect-based tele-medicine tool for remote motion and function assessment. Stud Health Technol Inform 2014;196:215-221.